By Counterforce Health Team in Strimvelis (autologous CD34+ ADA-SCID gene therapy) —

Work With Your Doctor to Get Strimvelis Gene Therapy Approved by UnitedHealthcare in Michigan: Provider Partnership Guide

Answer Box: Your Path to Approval

Getting Strimvelis (autologous CD34+ ADA-SCID gene therapy) approved by UnitedHealthcare in Michigan requires strong provider partnership. Your doctor must submit prior authorization with confirmed ADA enzyme deficiency (<1% normal), genetic testing, HSCT ineligibility documentation, and medical necessity letter citing life-threatening urgency. If denied, request peer-to-peer review within 14 days, then file Michigan DIFS external review within 127 days. Start today: Schedule an appointment to review your diagnosis documentation and discuss the SR-TIGET Milan treatment plan with your immunologist.

Table of Contents

  1. Set Your Goal: What Approval Requires
  2. Visit Prep: Gathering Your Medical Story
  3. Building Your Evidence Kit
  4. The Medical Necessity Letter Structure
  5. Supporting Your Doctor's Peer-to-Peer Review
  6. After-Visit Documentation
  7. Respectful Persistence Strategy
  8. Appeals Playbook for Michigan
  9. FAQ

Set Your Goal: What Approval Requires

Your partnership with your doctor centers on proving medical necessity for Strimvelis, a life-saving gene therapy available only at SR-TIGET in Milan, Italy. UnitedHealthcare requires prior authorization for this orphan drug, but as an FDA-designated orphan therapy, it's exempt from step therapy requirements.

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for outpatient specialty drugs UHC Provider Portal UHC PA Guidelines
Orphan Drug Exception No step therapy required OptumRx formulary Premium Formulary
Diagnosis Code ICD-10 D81.110 (ADA-SCID) Clinical documentation Medical records
Billing Code HCPCS J3590 (unclassified biologics) Provider billing UHC PA requirements
Appeal Deadline 127 days for Michigan external review DIFS website Michigan DIFS

Your role: Provide complete medical history, coordinate specialist appointments, and ensure all documentation reaches your provider promptly.

Your doctor's role: Submit comprehensive PA with genetic/biochemical proof, document HSCT ineligibility, and prepare for potential peer-to-peer discussion with UHC medical director.

Visit Prep: Gathering Your Medical Story

Before meeting with your immunologist or pediatric specialist, compile a detailed timeline that demonstrates the severity and progression of your ADA-SCID.

Symptom Timeline Worksheet

Create a chronological record including:

  • Infection history: Dates, types (bacterial, viral, fungal), hospitalizations, antibiotic courses
  • Growth/development: Weight/height percentiles, developmental delays, feeding difficulties
  • Laboratory trends: T-cell counts, immunoglobulin levels, ADA enzyme activity results
  • Treatment responses: PEG-ADA therapy duration, side effects, effectiveness decline

Failed Treatment Documentation

Your provider needs evidence of:

  1. PEG-ADA enzyme replacement therapy: Pharmacy records, dosing history, lab monitoring, reasons for discontinuation
  2. Supportive care failures: Prophylactic antibiotics, IVIG therapy, isolation measures
  3. HSCT evaluation: HLA typing results, donor search outcomes, transplant center consultation notes
Tip: Request copies of all lab reports and specialist notes at least one week before your appointment. Missing documentation delays PA submission and approval.

Building Your Evidence Kit

Work with your care team to assemble comprehensive documentation that meets UnitedHealthcare's medical necessity standards.

Core Diagnostic Evidence

Test Category Required Documentation Lab Values/Results
Biochemical ADA enzyme activity <1% of normal (erythrocytes/plasma)
Genetic Clinical genetics report Biallelic pathogenic ADA gene variants
Immunologic Flow cytometry T⁻ B⁻ NK⁻ SCID phenotype
Clinical Growth charts, infection log Failure to thrive, recurrent infections

HSCT Ineligibility Proof

Your provider must document why hematopoietic stem cell transplant isn't viable:

  • HLA typing report: No 10/10 matched related donor available
  • Donor search results: National Marrow Donor Program (NMDP) search showing no suitable unrelated donor or high-risk match
  • Transplant center evaluation: Letter stating contraindications or poor prognosis

Published Guidelines and References

Help your provider locate evidence-based support:

  • European Medicines Agency (EMA) approval documentation for Strimvelis
  • NICE Technology Appraisal recommending Strimvelis when no matched related donor available
  • Primary immunodeficiency treatment guidelines from ESID or ASID

The Medical Necessity Letter Structure

Your provider's letter to UnitedHealthcare should follow this proven framework:

1. Patient Identification and Diagnosis

"[Patient name] is a [age]-year-old with confirmed adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID), ICD-10 D81.110, diagnosed via genetic testing revealing biallelic pathogenic variants in the ADA gene and biochemical confirmation of ADA enzyme activity <1% of normal."

2. Clinical Rationale and Urgency

"Without definitive treatment, ADA-SCID is universally fatal within the first two years of life due to progressive immune failure and overwhelming infections. This patient has experienced [specific infections/hospitalizations] despite optimal supportive care."

3. Treatment Failures and Contraindications

"The patient has failed/is intolerant to PEG-ADA enzyme replacement therapy [specify reasons]. Hematopoietic stem cell transplantation is not feasible due to [lack of matched donor/medical contraindications]."

4. Requested Treatment Details

"I am requesting approval for Strimvelis (autologous CD34+ gene therapy) administered at San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET) in Milan, Italy, the sole authorized treatment center. This one-time therapy costs approximately €594,000."

5. Evidence-Based Support

Include citations from:

  • EMA marketing authorization documents
  • NICE cost-effectiveness analysis
  • Peer-reviewed outcomes data from SR-TIGET

6. Risks of Delay

"Delaying treatment risks irreversible immune damage, life-threatening infections, and potential mortality. Early intervention optimizes outcomes."

From our advocates: We've seen strongest approvals when providers emphasize the "rescue therapy" nature of Strimvelis—it's not experimental but rather the established standard of care when HSCT isn't possible. Frame it as preventing an inevitable fatal outcome rather than an elective treatment option.

Supporting Your Doctor's Peer-to-Peer Review

If UnitedHealthcare initially denies coverage, your provider can request a peer-to-peer discussion with a UHC medical director within 14 days of the adverse determination.

Preparation Checklist for Your Provider

Before the call:

  • Review all diagnostic documentation
  • Prepare 2-3 key references (EMA approval, NICE recommendation, survival data)
  • Have patient-specific timeline ready (infections, hospitalizations, treatment failures)
  • Confirm understanding of SR-TIGET protocol and logistics

Key Talking Points to Discuss

Help your provider prepare these arguments:

  1. Diagnostic certainty: "Genetic and biochemical testing conclusively confirms ADA-SCID"
  2. Standard of care: "Strimvelis is EMA-approved and NICE-recommended for this exact indication"
  3. No alternatives: "HSCT is contraindicated; PEG-ADA has failed/is inappropriate"
  4. Urgency: "Progressive immune deterioration makes delay life-threatening"
  5. Evidence base: "Published outcomes from SR-TIGET demonstrate 70%+ survival at 3 years"

Making Yourself Available

Offer to be present during the peer-to-peer call or available by phone to provide patient/family perspective on:

  • Quality of life impact
  • Previous treatment burden
  • Understanding of risks and benefits
  • Commitment to travel and follow-up care

After-Visit Documentation

Maintain detailed records of all interactions to support potential appeals.

What to Save

  • Portal messages: Screenshots of all communications with your provider's office
  • Prior authorization submissions: Confirmation numbers, submission dates
  • Peer-to-peer requests: Documentation of scheduling and outcomes
  • Denial letters: Complete copies with specific reasons cited

Follow-Up Communication

Use your provider's patient portal to:

  • Confirm receipt of all documentation
  • Request updates on PA status every 5-7 business days
  • Share any new symptoms or urgent changes in condition

Sample portal message: "Hi [Provider name], following up on our discussion about Strimvelis PA submission to UnitedHealthcare. Can you please confirm you received the genetic testing report and HLA typing results I provided? Also, do you have an estimated timeline for submission? Please let me know if you need any additional documentation from me."

Respectful Persistence Strategy

Maintaining momentum without overwhelming your care team requires strategic communication.

Communication Cadence

  • Week 1-2: Daily check on documentation gathering
  • Week 3-4: Every 2-3 days on PA submission status
  • Week 5+: Weekly updates unless urgent developments

Escalation Path

  1. Primary provider: Start with your immunologist or pediatric specialist
  2. Care coordinator: Request assignment of dedicated case manager
  3. Department chief: If delays persist, respectfully request supervisor involvement
  4. Patient advocate: Many hospitals have patient advocacy services

Professional Escalation Scripts

To request care coordinator: "Given the complexity of this rare disease case and international treatment requirements, would it be possible to assign a dedicated case coordinator to help navigate the insurance approval process?"

To request supervisor involvement: "I understand my provider is very busy, but given the time-sensitive nature of ADA-SCID treatment, would it be appropriate to involve a department supervisor to help expedite this process?"

Appeals Playbook for Michigan

When UnitedHealthcare denies coverage, Michigan offers robust appeal rights through the Department of Insurance and Financial Services (DIFS).

Step-by-Step Appeals Process

Step Timeline Action Required Where to Submit
Internal Appeal 30-60 days from denial Submit appeal letter with new evidence UHC member portal or appeals address
External Review Within 127 days of final denial File DIFS External Review form DIFS Online Portal
Expedited Review Within 127 days (urgent cases) Physician letter stating delay risks life/health Same DIFS portal with urgency documentation

Required Documents for DIFS External Review

  • FIS 0018 form (Health Care Request for External Review)
  • Complete denial letter from UnitedHealthcare
  • Physician letter certifying medical necessity and urgency
  • All medical records supporting the request
  • Copy of insurance policy or benefits summary
Note: Michigan's 127-day deadline is longer than the federal 120-day standard, giving you extra time to gather comprehensive documentation.

Expedited Review Criteria

Request expedited (72-hour) review if:

  • Delay would jeopardize life or health
  • Denial is for urgently needed service
  • Your physician provides written attestation of urgency

Contact DIFS: 877-999-6442 for questions about the external review process.

FAQ

How long does UnitedHealthcare prior authorization take for Strimvelis? Standard PA decisions are made within 15 business days for non-urgent requests. Urgent/expedited requests receive decisions within 72 hours. Complex cases involving rare diseases may require additional clinical review time.

What if Strimvelis isn't on UnitedHealthcare's formulary? As an FDA-designated orphan drug, Strimvelis is exempt from step therapy requirements even if non-formulary. Your provider can request formulary exception based on medical necessity and lack of therapeutic alternatives.

Can I request an expedited appeal in Michigan? Yes, Michigan DIFS offers expedited external review (72-hour decision) when your physician certifies that delay would jeopardize your life, health, or ability to regain maximum function.

Does UnitedHealthcare cover international treatment centers? Standard UHC plans typically exclude out-of-network international care. However, when treatment is only available at specific centers of excellence (like SR-TIGET for Strimvelis), coverage exceptions may be possible through medical necessity appeals.

How much does Strimvelis cost, and are there financial assistance options? The list price is approximately €594,000 per patient. Orchard Therapeutics may offer patient assistance programs. Additionally, some foundations provide grants for rare disease treatments requiring international travel.

What happens if my internal appeal is denied? You have 127 days from UnitedHealthcare's final adverse determination to file an external review with Michigan DIFS. The independent review organization's decision is binding on your insurer.

When navigating complex insurance approvals for rare disease treatments, having the right support makes all the difference. Counterforce Health specializes in turning insurance denials into successful appeals by creating targeted, evidence-backed submissions that align with payer requirements. Their platform helps patients, clinicians, and specialty pharmacies get prescription drugs approved by identifying denial reasons and crafting point-by-point rebuttals using the right clinical evidence and procedural requirements.

For additional support with your UnitedHealthcare appeal in Michigan, Counterforce Health can help ensure your submission meets all payer-specific requirements and includes the strongest possible medical necessity documentation.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance company for guidance specific to your situation. Coverage policies and appeal processes may change; verify current requirements with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.